Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Foot Ulcer, DiabeticDiabetes Complications
Interventions
DRUG

MRE0094

Gel, 500 mcg/g once each day

DRUG

Vehicle gel

Gel administered once per day

Trial Locations (19)

10461

Calvary Hospital, The Bronx

11776

North Shore Podiatry Group, Port Jefferson Station

18104

Lehigh Valley Podiatry Associates, Allentown

27713

UNC Wound Care Clinic, Durham

27834

Eastern Carolina Foot & Ankle Specialists, Greenville

30058

Ankle and Foot Specialist of Atlanta, Lithonia

33136

University of Miami, Miami

33813

Karr Foot & Leg Centers, Lakeland

48152

Foot Healthcare Associates, Livonia

49770

Northern Michigan Hospital, Petoskey

53215

St. Luke's Medical Center, Milwaukee

75231

Limb Salvage Center, Dallas

79410

Southwest Regional Wound Care, Lubbock

80220

Diabetic Foot & Wound Center, Denver

85015

Associated Foot & Ankle Specialists, LLC, Phoenix

85723

Southern Arizona VA Health Care System, Tucson

90063

Innovative Medical Technologies, Los Angeles

93710

Roy O. Kroeker, DPM, Fresno

06515

North American Center for Limb Preservation, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY